Anti-CXCR4 monoclonal antibody - Eli Lilly

Drug Profile

Anti-CXCR4 monoclonal antibody - Eli Lilly

Alternative Names: CXCR4 Mab - Eli Lilly

Latest Information Update: 08 Feb 2012

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jan 2012 Discontinued - Phase-I for Cancer in USA (Parenteral)
  • 16 Jun 2011 Phase-I clinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top